Total trials
125
Active
57
Phase 3
5
Total enrollment
2,046,663
Pipeline matrix
Showing 40 of 45 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| IBI311 | — | — | — | — | — | 3 | |
| Glucocorticoids | — | — | — | — | — | 2 | |
| Carvedilol and alverine | — | — | — | — | — | 1 | |
| Low-dose LC-Z300-01 twice daily in blinding | — | — | — | — | — | 1 | |
| High-dose LC-Z300-01 twice daily in blinding | — | — | — | — | — | 1 | |
| High-dose LCZ300-1 twice daily in open-label | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | — | 3 | |
| Oxaliplatin | — | — | — | — | — | 3 | |
| Bevacizumab | — | — | — | — | — | 3 | |
| Tislelizumab | — | — | — | — | 2 | ||
| Pembrolizumab | — | — | — | — | — | 1 | |
| Mesenchymal stem cell derived exosome nebulization combined with compound methoxyphenamine | — | — | — | — | — | 1 | |
| Normal saline nebulization combined with the compound methoxyphenamine | — | — | — | — | — | 1 | |
| CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE | — | — | — | — | — | 1 | |
| FOLFIRI + Vemurafenib + Cetuximab | — | — | — | — | — | 1 | |
| FOLFIRI ± Bevacizumab | — | — | — | — | — | 1 | |
| chidamide, regorafenib, and iparomlimab/tuvonralimab | — | — | — | — | — | 1 | |
| Anlotinib Plus Toripalimab | — | — | — | — | — | 1 | |
| anlotinib and sintilimab | — | — | — | — | — | 1 | |
| Serplulimab | — | — | — | — | — | 1 | |
| S-1 | — | — | — | — | — | 1 | |
| Injection of MSC303 | — | — | — | — | — | 1 | |
| Prednisone | — | — | — | — | — | 1 | |
| Alverine Citrate | — | — | — | — | — | 1 | |
| PSMA-UCAR T | — | — | — | — | — | 1 | |
| HNF4α srRNA | — | — | — | — | — | 2 | |
| Rifaximin | — | — | — | — | 4 | ||
| CD-801 | — | — | — | — | — | 2 | |
| MTS109 | — | — | — | — | — | 1 | |
| Standard Androgen Deprivation Therapy | — | — | — | — | — | 1 | |
| Standard Endocrine Therapy | — | — | — | — | — | 1 | |
| Chimeric antigen receptor modified T cells | — | — | — | — | — | 1 | |
| Enhanced autologous PSMA-CAR T | — | — | — | — | — | 1 | |
| anti-IGF-1R mAb | — | — | — | — | — | 1 | |
| Rifaximin-α | — | — | — | — | — | 1 | |
| Experimental: CAR-T cells | — | — | — | — | — | 1 | |
| CD-GA-102 | — | — | — | — | — | 1 | |
| anti-CD70-CAR-T cells | — | — | — | — | — | 1 | |
| Creon（Pancreatin Enteric-coated Capsules） | — | — | — | — | — | 1 | |
| CAR-T cells | — | — | — | — | — | 1 |
5 more active programs hidden
Next readouts
- 2024-10-01
- 2024-10-31
- 2025-01-28
- 2025-06-30
- 2025-07
- 2025-07-30
- 2025-09-30
- 2025-10-31
- 2025-11-11
- 2025-12
Top conditions
- Multiple Myeloma9
- Colorectal Cancer8
- Diabetes5
- Diabetes Mellitus4
- Thyroid Associated Ophthalmopathies4
- Cirrhosis3
- Hypertension, Portal3
- Ossification of Posterior Longitudinal Ligament3
Frequently asked questions about Shanghai Changzheng Hospital
- How many clinical trials does Shanghai Changzheng Hospital have on ClinicalTrials.gov?
- Shanghai Changzheng Hospital is listed as the lead sponsor on 125 clinical trials in ClinicalTrials.gov, 57 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Shanghai Changzheng Hospital's trials are in Phase 3?
- 5 of Shanghai Changzheng Hospital's trials are in Phase 3, spread across 45 active drug programs.
- What therapeutic areas does Shanghai Changzheng Hospital focus on?
- Shanghai Changzheng Hospital's most-studied conditions on ClinicalTrials.gov are Multiple Myeloma, Colorectal Cancer, Diabetes, Diabetes Mellitus, Thyroid Associated Ophthalmopathies.
- When are Shanghai Changzheng Hospital's next clinical trial readouts?
- Shanghai Changzheng Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer”, expected around 2024-10-01.